Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA®
LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
